In the present study, we demonstrated that PIK3CA mutation contributes to MEK inhibitor primary resistance and that Akt is activated in response to MEK inhibitor treatment in the PIK3CA-mutated colorectal cancer cell lines DLD-1 and HT-29. This evidence concerns the gene MAP2K7 and colorectal cancer.